Melatonin as an inducing factor for multiple sclerosis

Kuklina E.M.

doi:https://doi.org/10.17116/jnevro201611651102-105

Close metadata

Recommended articles:

A clinical case of X-linked adrenoleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107

Cognitive impairment in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73

Artificial intelligence capabilities in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21

Molecular mechanisms of acute disseminated encephalomyelitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):7-11

The role of monocytes in the immunopathogenesis of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):23-27

Results of a 5-year project for the early diagnosis of multiple sclerosis in first-line blood relatives (RADIRS program). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):28-33

Current epidemiology of MS with onset in childhood and adolescence (pediatric multiple sclerosis). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):34-38

Features of the clinical course of multiple sclerosis as a factor in persistent disability. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):39-44

Angiotensin model as a new approach to study of mesenchymal stem cell senescence. Russian Cardiology Bulletin. 2025;(2):20-26

Associations between salivary melatonin and periodontal disease: a systematic review and meta-analysis. Stomatology. 2025;(3):87-96

Abstract:

Melatonin is one of the most multifunctional regulators in the organism. It plays a key role in the control of nerve, endocrine, and immune systems. Due to hormone neuroprotective activity, the possibility is now discussed on its clinical usage in treating neurodegenerative diseases, including multiple sclerosis. At the same time, melatonin is an effective regulator of immune reactions, in part, the reactions toward autoantigens. In this respect, the subset of T lymphocytes producing IL-17 (Th17) is of special interest. As the Th17 subset plays a key role in multiple sclerosis pathogenesis, the immunomodulating hormone effects toward Th17, may, in theory, nullify its positive neuroprotective activity.

Keywords:

melatonin

immunity

Th17

multiple sclerosis

Authors:

Kuklina E.M.

FGBUN "Institut kologii i genetiki mikroorganizmov" Ural'skogo otdeleniia RAN, Perm'

Close metadata

References:

Sapède D, Cau E. The pineal gland from development to function. Curr Top Dev Biol. 2013;106:171-215. doi: 10.1016/b978-0-12-416021-7.00005-5.
Acuña-Castroviejo D, Escames G, Venegas C, Díaz-Casado ME, Lima-Cabello E, López LC, Rosales-Corral S, Tan DX, Reiter RJ. Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci. 2014;71:2997-3025. doi: 10.1007/s00018-014-1579-2.
Constantinescu CS, Hilliard B, Ventura E, Rostami A. Luzindole, a melatonin receptor antagonist, suppresses experimental autoimmune encephalomyelitis. Pathobiology. 1997;65:190-194. doi: 10.1159/000164122.
Sandyk R. Influence of the pineal gland on the expression of experimental allergic encephalomyelitis: Possible relationship to the aquisition of multiple sclerosis. Int J Neurosci. 1997;90:129-133. doi: 10.3109/00207459709000632.
Alonso-Alconada D, Alvarez A, Lacalle J, Hilario E. Histological study of the protective effect of melatonin on neural cells after neonatal hypoxia-ischemia. Histol Histopathol. 2012;27:771-783.
Ramírez-Rodríguez G, Klempin F, Babu H, Benítez-King G, Kempermann G. Melatonin modulates cell survival of new neurons in the hippocampus of adult mice. Neuropsychopharmacology. 2009;34:2180-2191. doi: 10.1038/npp.2009.46.
Daglioglu E, Serdar Dike M, Kilinc K, Erdogan D, Take G, Ergungor F, Okay O, Biyikli Z. Neuroprotective effect of melatonin on experimental peripheral nerve injury: an electron microscopic and biochemical study. Cent Eur Neurosurg. 2009;70:109-114. doi: 10.1055/s-0029-1220712.
Villapol S, Fau S, Renolleau S, Biran V, Charriaut-Marlangue C, Baud O. Melatonin promotes myelination by decreasing white matter inflammation after neonatal stroke. Pediatr Res. 2011;69:51-55. doi: 10.1203/pdr.0b013e3181fcb40b.
Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, Ma L, Shah B, Panopoulos AD, Schluns KS, Watowich SS, Tian Q, Jetten AM, Dong C. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity. 2008;28:29-39. doi: 10.1016/j.immuni.2007.11.016.
Kuklina EM. Melatonin as potential inducer of Th17 cell differentiation. Medical Hypothesis. 2014;83:404-406. doi: 10.1016/j.mehy.2014.07.006.
Jadidi-Niaragh F, Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand J Immunol. 2011;74:1-13. doi: 10.1111/j.1365-3083.2011.02536.x.
Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K, Iwakura Y. Il-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol. 2006;177:566-573. doi: 10.4049/jimmunol.177.1.566.
Pozo D, García-Mauriño S, Guerrero JM, Calvo JR. mRNA expression of nuclear receptor RZR/RORa, melatonin membrane receptor MT1, and hydroxindole-O-methyltransferase in different populations of human immune cells. J Pineal Res. 2004;37:48-54. doi: 10.1111/j.1600-079x.2004.00135.x.
Ekmekcioglu C. Melatonin receptors in humans: biological role and clinical relevance. Biomed Pharmacother. 2006;60:97-108. doi: 10.1016/j.biopha.2006.01.002.
Ragonda F, Diederich M, Ghibelli L. Melatonin: a pleiotropic molecule regulating inflammation. Biochem Pharmacol. 2010;80:1844-1852. doi: 10.1016/j.bcp.2010.07.041.
García-Mauriño S, Gonzalez-Haba MG, Calvo JR. Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4+ cells: A possible nuclear receptor-mediated mechanism involving t helper type 1 lymphocytes and monocytes. J Immunol. 1997;159:574-581.
Аrias J, Melean E, Valero N. Effect of melatonin on lymphocyte proliferation and production of interleukin 2 (IL-2) and interleukin 1 beta (IL-1 beta) in mice splenocytes. Invest Clin. 2003;44:41-50.
Espino J, Rodriguez AB, Pariente JA. The inhibition of TNF-alpha-induced leucocyte apoptosis by melatonin involves membrane receptor MT1/MT2 interaction. J Pineal Res. 2013;54:442-452. doi: 10.1111/jpi.12042.
Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine. 2005;27:101-110.
Kato K, Hirai K, Nishiyama K et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005;48:301-310. doi: 10.1016/j.neuropharm.2004.09.007.
Lardone PJ, Guerrero JM, Fernandez-Santos JM, Rubio A, Martin-Lacave I, Carrillo-Vico A. Melatonin synthesized by T lymphocytes as a ligand of the retinoid acid-related orphan receptor. J Pineal Res. 2011;51:454-462. doi: 10.1111/j.1600-079x.2011.00909.x.
Wiesenberg I, Missbach M, Kahlen J-P, Schrader M, Carsten C. Transcriptional activation of the nuclear receptor RZRα by the pineal gland hormone melatonin and dentification of CGP52608 as a synthetic ligand. Nucleic Acid Res. 1995;23:327-333. doi: 10.1093/nar/23.3.327.
Kojima H, Muromoto R, Takahashi M. Inhibitory effects of azole-type fungicides on interleukin-17 gene expression via retinoic acid receptor-related orphan receptors α and γ. Toxicol Appl Pharmacol. 2012;259:338-345. doi: 10.1016/j.taap.2012.01.011.
Carrillo-Vico A, Lardone PJ, Naji L. Beneficial pleiotropic actions of melatonin in an experimental model of septic shock in mice: Regulation of pro-/anti-inflammatory cytokine network, protection against oxidative damage and anti-apoptotic effects. J Pineal Res. 2005;39:400-408. doi: 10.1111/j.1600-079x.2005.00265.x.
Park H, Li Z, Yang XO. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6:1133—1141. doi: 10.1038/ni126.1
Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Ann Rev Immunol. 2009;27:485-517.
Ivanov II, McKenzie BS, Zhou L. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126:1121-1133.
Arjona A, Silver AC, Walker WE, Fikrig E. Immunity’s fourth dimension: approaching the circadian-immune connection. Trends Immunol. 2012;33:607-612. doi: 10.1016/j.it.2012.08.007.
Mazzoccoli G, Muscarella LA, Fazio VM. Antiphase signaling in the neuroendocrine-immune system in healthy humans. Biochem Pharmacol. 2011;65:275-279. doi: 10.1016/j.biopha.2011.02.002.
Srinivasan V, Spence DW, Trakht I, Pandi-Perumal SR, Cardinali DP, Maestroni GJ. Immunomodulation by melatonin:its significance for seasonally occurring diseases. Neuroimmunomodulation. 2008;15:93-101. doi: 10.1159/000148191.
Greene MW. Circadian rhythms and tumor growth. Cancer Lett. 2012;318:115-123. doi: 10.1016/j.canlet.2012.01.001.
Atanassova PA, Terzieva DD, Dimitrov BD. Impared nocturnal melatonin in acute phase of ishaemic stroke: cross-sectional matched case-control analysis. J Neuroendocrinol. 2009;21:657-663. doi: 10.1111/j.1365-2826.2009.01881.x.
Sulli A, Maestroni GJ, Villaggio B. Melatonin serum levels in rheumatoid arthritis. Ann NY Acad Sci. 2002;966:276-283. doi: 10.1111/j.1749-6632.2002.tb04227.x.
Ghorbani A, Salari M, Shaygannejad V, Norouzi R. The role of melatonin in the pathogenesis of multiple sclerosis: a case-control study. Int J Prev Med. 2013;4:180-184.
Tan D, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res. 2007;42:28-42. doi: 10.1111/j.1600-079x.2006.00407.x.
Kostoglou-Athanassiou I. Therapeutic applications of melatonin. Ther Adv Endocrinol Metab. 2013;4:13-24.
Bagnaresi P, Nakabashi M, Thomas AP, Reiter RJ, Garcia CR. The role of melatonin in parasite biology. Mol Biochem Parasitol. 2012;181:1-6. doi: 10.1016/j.molbiopara.2011.09.010.
Srinivasan V, Mohamed M, Kato H. Melatonin in bacterial and viral infections with focus on sepsis: A review. Recent Pat Endocr Metab Immune Drug Discov. 2012;6:30-39. doi: 10.2174/187221412799015317.
Mediavilla MD, Sanchez-Barcelo EJ, Tan DX, Manchester L, Reiter RJ. Basic mechanisms involved in the anti-cancer effects of melatonin. Curr Med Chem. 2010;17:4462-4481. doi: 10.2174/092986710794183015.
Srinivasan V, Pandi-Perumal SR, Brzezinski A, Bhatnagar KP, Cardinali DP. Melatonin, immune function and cancer. Recent Pat Endocr Metab Immune Drug Discov. 2011;5:109-123. doi: 10.2174/187221411799015408.
Srinivasan V, Cardinali DP, Srinivasan US. Therapeutic potential of melatonin and its analogs in Parkinson’s disease: focus on sleep and neuroprotection. Ther Adv Neurol Disord. 2011;4:297-317. doi: 10.1177/1756285611406166.
Lin L, Huang QX, Yang SS, Chu J, Wang JZ, Tian Q. Melatonin in Alzheimer’s disease. Int J Mol Sci. 2013;14:14575-14593.
Matusevicius D, Kivisäkk P, He B, Kostulas N, Ozenci V, Fredrikson S, Link H. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler. 1999;5:101-104. doi: 10.1177/135245859900500206.
Akpinar Z, Tokgoz S, Gokbel H, Okudan N, Uguz F, Yilmaz G. The association of nocturnal serum melatonin levels with major depression in patients with acute multiple sclerosis. Psychiatry Res. 2008;161:253-257. doi: 10.1016/j.psychres.2007.11.022.
Sandyk R. Diurnal variations in vision and relations to circadian melatonin secretion in multiple sclerosis. Int J Neurosci. 1995;83:1-6. doi: 10.3109/00207459508986320.
Kang JC, Ahn M, Kim YS, Moon C, Lee Y, Wie MB, Lee YJ, Shin T. Melatonin ameliorates autoimmune encephalomyelitis through suppression of intercellular adhesion molecule-1. J Vet Sci. 2001;2:85-89.